Point cloud video (PCV) offers watching experiences in photorealistic 3D scenes with six-degree-of-freedom (6-DoF), enabling a variety of VR and AR applications. The user's Field of View (FoV) is more fickle with 6-DoF movement than 3-DoF movement in 360-degree video. PCV streaming is extremely bandwidth-intensive. However, current streaming systems require hundreds of Mbps bandwidth, exceeding the bandwidth capabilities of commodity devices. To save bandwidth, FoV-adaptive streaming predicts a user's FoV and only downloads point cloud data falling in the predicted FoV. But it is difficult to accurately predict the user's FoV even 2-3 seconds before playback due to 6-DoF. Misprediction of FoV or network bandwidth dips results in frequent stalls. To avoid rebuffering, existing systems would cause incomplete FoV and degraded experience, deteriorating the user's quality of experience (QoE). In this paper, we describe Fumos, a novel system that preserves interactive experience by avoiding playback stalls while maintaining high perceptual quality and high compression rate. We find a research gap in inter-frame redundant utilization and progressive mechaism. Fumos has three crucial designs, including (1) Neural compression framework with inter-frame coding, namely N-PCC, which achieves both bandwidth efficiency and high fidelity. (2) Progressive refinement streaming framework that enables continuous playback by incrementally upgrading a fetched portion to a higher quality (3) System-level adaptation that employs Lyapunov optimization to jointly optimize the long-term user QoE. Experimental results demonstrate that Fumos significantly outperforms Draco, achieving an average decoding rate acceleration of over 260×. Moreover, the proposed compression framework N-PCC attains remarkable BD-Rate gains, averaging 91.7% and 51.7% against the state-of-the-art point cloud compression methods G-PCC and V-PCC, respectively.

01 Jul 2023·Current Pharmaceutical BiotechnologyQ4 · MEDICINE

Fungal Metabolites: A Potential Source of Antidiabetic Agents with Particular Reference to PTP1B Inhibitors

Q4 · MEDICINE

Review

Author: Deshmukh, Sunil Kumar ; Agrawal, Shivankar ; Gupta, Manish K.

Abstract:Diabetes is a growing health concern worldwide because it affects people of all age groups and increases the risk of other diseases such as renal impairment and neural and cardiovascular disorders. Oral hypoglycemic drugs mainly control diabetes; however, their associated side effects limit their use in patients with other complications. PTP1B is a viable drug target to explore new antidiabetic drugs. PTP1B acts as a negative regulator of the insulin-signaling pathway, and therefore, PTP1B inhibitors display antihyperglycemic activity. Several classes of compounds from natural and synthetic sources act as PTP1B inhibitors. Fungi are comprehensive in their diversity and recognized as a valuable source for therapeutically active molecules. In recent years, researchers have reported diverse classes of fungal secondary metabolites as potent PTP1B inhibitors. Some metabolites such as 6-O-methylalaternin, fumosorinone A, nordivaricatic acid, and the divarinyl divarate showed good activity and can be taken forward as a lead to develop novel PTP1B inhibitors and antidiabetic drugs. Therefore, the present review focuses on the fungal metabolites identified in the last five years possessing PTP1B inhibitory activity. A total of 128 metabolites are reviewed. Their fungal species and source, chemical structure, and activity in terms of IC50 are highlighted.

01 Jan 2023·Mycobiology

Effect of Abiotic Factors on Fumosorinone Production from Cordyceps fumosorosea via Solid-State Fermentation.

Article

Author: Khan, Tahir ; Hou, Dong-Hai ; Yu, Hong ; Yang, Yin-Long ; Zhou, Jin-Na

Cordyceps fumosorosea is an important species in the genus of Cordyceps, containing a variety of bioactive compounds, including fumosorinone (FU). This study was a ground-breaking assessment of FU levels in liquid and solid cultures. The present study focused on the impacts of solid-state fermentation (SSF) using solid substrates (wheat, oat, and rice), as well as the effects of fermentation parameters (pH, temperature, and incubation period), on the generation of FU. All the fermentation parameters had significant effects on the synthesis of FU. In a study of 25 °C, 5.5 pH, and 21 days of incubation period combinations calculated -to give maximal FU production, it was found that the optimal values were 25 °C, 5.5 pH, and 21 days, respectively. In a solid substrate medium culture, FU could be produced from SSF. At 30 days, a medium composed of rice yielded the most FU (798.50 mg/L), followed by a medium composed of wheat and oats (640.50 and 450.50 mg/L), respectively. An efficient method for increasing FU production on a large scale could be found in this approach. The results of this study might have multiple applications in different industrial fermentation processes.

100 Deals associated with Fumosorinone

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Myeloid Leukemia	Preclinical	China	Hebei University	02 Dec 2015
Solid tumor	Preclinical	China	Hebei University	02 Dec 2015
Diabetes Mellitus	Preclinical	China	Hebei University	01 May 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Fumosorinone

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation